. 2013 Dec;347(3):599–606. doi: 10.1124/jpet.113.208801

TABLE 3.

Ability of an oxidative burst phenotypic probe to predict PLD clearance in patients

Linear regression of the oxidative burst probes and PLD CL in the 10 patients enrolled in the study. Values are reported for patients who received PLD (only) or PLD + carboplatin as their standard therapy for recurrent EOC.

Stimulant	All Patients (R², r_s)	PLD Only (R², r_s)	PLD + Carboplatin (R², r_s)
No stimulant (baseline cell ROS production)	0.61, 0.64,^‡	0.61, 0.6,*	0.0005, 0.4
E. coli (particulate)	0.46, 0.22,*	0.44, 0.2	0.26, 0.4
fMLP (physiologic)	0.54, 0.57,*	0.48, 0.7	0.14, 0.4,^‡
PMA (synthetic)	0.23, 0.72	0.21, 0.8	0.59, 0.8

fMLP, N-formyl-methionine-leucine-phenylalanine.

^‡

P ≤ 0.001; *P ≤ 0.05.